These 5 Houston-area research institutions have bright minds at work to battle COVID-19

research roundup

Houston researchers are working to provide COVID-19 solutions amid the pandemic. Getty Images

Since even the early days of COVID-19's existence, researchers all over the world were rallying to find a cure or potential vaccine — which usually take years to make, test, and get approved.

Houston researchers were among this group to put their thinking caps on to come up with solutions to the many problems of the coronavirus. From the testing of existing drugs to tapping into tech to map the disease, here are some research projects that are happening in Houston and are emerging to fight the pandemic.

Baylor College of Medicine evaluating potential COVID-fighting drug

Human Body Organs (Lungs Anatomy)

Baylor College of Medicine has identified a drug that could potentially help heal COVID-19 patients. Photo via bcm.edu

While Baylor College of Medicine has professionals attacking COVID-19 from all angles, one recent discovery at BCM includes a new drug for treating COVID-caused pneumonia.

BCM researchers are looking into Tocilizumab's (TCZ), an immunomodulator drug, effect on patients at Baylor St. Luke's Medical Center and Harris Health System's Ben Taub Hospital.

"The organ most commonly affected by COVID-19 is the lung, causing pneumonia for some patients and leading to difficulty breathing," says Dr. Ivan O. Rosas, chief of the pulmonary, critical care and sleep medicine section at BCM, in a news release.

TCZ, which has been used to successfully treat hyperimmune responses in cancer patients being treated with immunotherapy, targets the immune response to the coronavirus. It isn't expected to get rid of the virus, but hopefully will reduce the "cytokine storm," which is described as "the hyper-immune response triggered by the viral pneumonia" in the release.

The randomized clinical trial is looking to treat 330 participants and estimates completion of enrollment early next month and is sponsored by Genentech, a biotechnology company.

Texas A&M University leads drug testing

A Texas A&M University researcher is trying to figure out if an existing vaccine has an effect on COVID-19. Screenshot via youtube.com

A researcher from Texas A&M University is working with his colleagues on a short-term response to COVID-19. A vaccine, called BDG, has already been deemed safe and used for treatment for bladder cancer. BDG can work to strengthen the immune system.

"It's not going to prevent people from getting infected," says Dr. Jeffrey D. Cirillo, a Regent's Professor of Microbial Pathogenesis and Immunology at the Texas A&M Health Science Center, in a news release. "This vaccine has the very broad ability to strengthen your immune response. We call it 'trained immunity.'"

A&M leads the study in partnership with the University of Texas MD Anderson Cancer Center and Baylor College of Medicine in Houston, as well as Harvard University's School of Public Health and Cedars Sinai Medical Center in Los Angeles.

Texas A&M Chancellor John Sharp last week set aside $2.5 million from the Chancellor's Research Initiative for the study. This has freed up Cirillo's team's time that was previously being used to apply for grants.

"If there was ever a time to invest in medical research, it is now," Sharp says in the release. "Dr. Cirillo has a head start on a possible coronavirus treatment, and I want to make sure he has what he needs to protect the world from more of the horrible effects of this pandemic."

Currently, the research team is recruiting 1,800 volunteers for the trial that is already underway in College Station and Houston — with the potential for expansion in Los Angeles and Boston. Medical professionals interested in the trial can contact Gabriel Neal, MD at gneal@tamu.edu or Jeffrey Cirillo, PhD at jdcirillo@tamu.edu or George Udeani, PharmD DSc at udeani@tamu.edu.

"This could make a huge difference in the next two to three years while the development of a specific vaccine is developed for COVID-19," Cirillo says in the release.

Rice University is creating a COVID-19 map

Researchers at Rice University's Center for Research Computing's Spatial Studies Lab have mapped out all cases of COVID-19 across Texas by tapping into public health data. The map, which is accessible at coronavirusintexas.org, also identifies the number of people tested across the state, hospital bed utilization rate, and more.

The project is led by Farès el-Dahdah, director of Rice's Humanities Research Center. El-Dahdah used open source code made available by ESRI and data from the Texas Department of State Health Services and Definitive Healthcare.

"Now that the Texas Division of Emergency Management released its own GIS hub, our dashboard will move away from duplicating information in order to correlate other numbers such as those of available beds and the potential for increasing the number of beds in relation to the location of available COVID providers," el-Dahdah says in a press release.

"We're now adding another layer, which is the number of available nurses," el-Dahdah continues. "Because if this explodes, as a doctor friend recently told me, we could be running out of nurses before running out of beds."


Texas Heart Institute is making vaccines more effective

A new compound being developed at Texas Heart Institute could revolutionize the effect of vaccines. Photo via texasheart.org

Molecular technology coming out of the Texas Heart Institute and 7 HIlls Pharma could make vaccines — like a potential coronavirus vaccine — more effective. The oral integrin activator has been licensed to 7 Hills and is slated to a part of a Phase 1 healthy volunteer study to support solid tumor and infectious disease indications in the fall, according to a press release.

The program is led by Dr. Peter Vanderslice, director of biology at the Molecular Cardiology Research Laboratory at Texas Heart Institute. The compound was first envisioned to improve stem cell therapy for potential use as an immunotherapeutic for certain cancers.

"Our research and clinical colleagues are working diligently every day to advance promising discoveries for at risk patients," says Dr. Darren Woodside, co-inventor and vice president for research at the Texas Heart Institute, in the release. "This platform could be an important therapeutic agent for cardiac and cancer patients as well as older individuals at higher risk for infections."

University of Houston's nanotech health monitor

UH researchers have developed a pliable, thin material that can monitor changes in temperature. Photo via uh.edu

While developed prior to the pandemic, nanotechnology out of the University of Houston could be useful in monitoring COVID patients' temperatures. The material, as described in a paper published by ACS Applied Nano Materials, is made up of carbon nanotubes and can indicate slight body temperature changes. It's thin and pliable, making it ideal for a wearable health tech device.

"Your body can tell you something is wrong before it becomes obvious," says Seamus Curran, a physics professor at the University of Houston and co-author on the paper, in a news release.

Curran's nanotechnology research with fellow researchers Kang-Shyang Liao and Alexander J. Wang, which also has applications in making particle-blocking face masks, began almost 10 years ago.
Doris Taylor from the Texas Heart Institute has been named to the National Academy of Inventors.

Houston inventor receives national recognition for leading innovation

Leading lady

A Houston inventor is being recognized for her leadership within cardiovascular regenerative medicine. Doris A. Taylor from the Texas Heart Institute has been named among the National Academy of Inventors' 54 academic inventors to the spring 2019 class of NAI Senior Members.

Taylor's work involves finding alternatives for the current practices for organ transplants, including the whole organ decellularization/recellularization technologies she developed in 2008.

"Dr. Taylor's work has revolutionized the field by making it possible to bioengineer scaffolds that effectively mimic natural organs," says Dr. Darren Woodside, Texas Heart Institute's vice president for research, in a news release. "The three U.S. patents she currently holds have spun off 28 international patents, stimulating the worldwide tissue engineering industry. Her current research team is refining these technologies and developing others, potentially revolutionizing the transplantation industry and eliminating wait lists for life-saving transplantable organs."

NAI selects its honorees by identifying their impact on the welfare of society, the release reads, and have proven success with their patents, licensing, and commercialization.

NAI Senior Members are active faculty, scientists and administrators from its Member Institutions who have demonstrated remarkable innovation producing technologies that have brought, or aspire to bring, real impact on the welfare of society. They also have proven success in patents, licensing and commercialization.

An individual's nomination for the NAI Senior Member class by its supporting institution is a distinct honor and a significant way for the organization to publicly recognize its innovators on a national level.At their host institutions, Senior Members foster a spirit of innovation, while educating and mentoring the next generation of inventors.

The new class of NAI Senior Members includes representatives from 32 institutions. Texas A&M University has two researchers in the class — Robert Balog, an associate professor in the Department of Electrical and Computer Engineering, and Balakrishna Haridas, a professor of practice in the Department of Biomedical Engineering and executive director for technology commercialization and entrepreneurship for the Texas A&M Engineering Experiment Station.

This latest class of NAI Senior Members represents 32 research universities and government and non-profit research institutes. They are named inventors on over 860 issued U.S. patents. In February, two Houston inventors were named to the inaugural class of senior members.

"NAI Member Institutions support some of the most elite innovators on the horizon. With the NAI Senior Member award distinction, we are recognizing innovators that are rising stars in their fields," says Paul R. Sanberg, NAI president, in the release. "This new class is joining a prolific group of academic visionaries already defining tomorrow."
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Chevron's Houston-based venture arm launches $300M fund focusing on low-carbon tech

show me the money

Chevron Corp.'s investment arm has launched a $300 million fund that will focus on low-carbon technology.

Chevron Technology Ventures LLC's Future Energy Fund II builds on the success of the first Future Energy Fund, which kicked off in 2018 and invested in more than 10 companies specializing in niches like carbon capture, emerging mobility, and energy storage. The initial fund contained $100 million.

"The new fund will focus on innovation likely to play a critical role in the future energy system in industrial decarbonization, emerging mobility, energy decentralization, and the growing circular carbon economy," Houston-based Chevron Technology Ventures says in a February 25 release.

Future Energy Fund II is the eighth venture fund created by Chevron Technology Ventures since its establishment in 1999. In 2019, the investment arm started a $90 million fund to invest in startups that can help accelerate the oil and gas business of San Ramon, California-based Chevron.

Chevron Technology Ventures' portfolio for low-carbon technology comprises a dozen companies: Blue Planet, Carbon Clean, Carbon Engineering, ChargePoint, Eavor, Infinitum Electric, Natron Energy, Spear Power Systems, Svante, Voyage, Vutility, and Zap Energy.

Only one of the companies in the low-carbon portfolio is based in Texas — Infinitum Electric, located in Round Rock. However, Chevron Technology Ventures is active in the Houston entrepreneurial ecosystem as a participant in the Rice Alliance for Technology and Entrepreneurship, Greentown Labs, The Cannon, and The Ion. Chevron's investment arm was the first tenant at The Ion.

In an August 2020 interview with InnovationMap, Barbara Burger, president of Chevron Technology Ventures, said the investment arm places a priority on helping advance entrepreneurship in Houston. "It is our home court," she said.

Burger said that for Houston to succeed in energy innovation, companies, government agencies, investment firms, and universities must rally around the city.

"We're doing a lot of things right — almost in spite of the world being crazy. … I think constancy of purpose is important," she said. "Despite the headwinds from COVID and despite the headwinds that industries are facing, we need to stay committed to that."

Burger noted that innovation "is not a straight path."

"We've got to plant a bunch of these seeds and see how they grow — we need to water them every day, and then I think we'll have a beautiful garden," she said.

Now's the time to find innovation opportunities in a trustless world, says this Houston expert

guest column

Hidden beneath all the recent events in the technology work, stock market, political landscape, and most of the social problems we see today lies one underlying trend. A trend so powerful that it's causing disruption in nearly every institution out there, and changing the business landscape faster than anyone can keep up.

Trust is gone. I mean completely gone.

At this point, the examples of this are too numerous to list but let's look at the past several months in the United States. In that short period, we saw an incredibly contentious election process, big tech disable the primary communication of a world leader, a mass exodus do decentralized messaging, an explosion in the defi industry and crypto, and a once promising vaccine process somehow not be effective despite being the primary conversation topic for everyone.

And this was all before a bunch of social media users treated the world's greatest stock market like a game, and far after we saw a country divided into two by racial movements, and we have yet to even get to things such as the Russian hacks.

We're left with an absolute mess of a situation where every social contract seems to be broken and the default response to any sort of central authority is being reevaluated. Without doubt we'll eventually figure out some great long-term answers, but at the speed at which the business world works today, it's going to be messy.

Luckily, mess creates opportunity and within all this disruption lies many golden nuggets of opportunity. The last twelve months was likely a watershed moment in key areas and as innovators, and business people — and it's our job to find them. It's what we signed up for and, for many of us, why we do what we do.

If there was ever a time to invest heavily in innovative technologies, today is it. Most of the time businesses are very resistant to change. Their default answer is always "no," and this puts innovators in a constant search of early adopters. But today, we see a different landscape. Businesses of all sizes and industries have been tossed around like a toy ship in an ocean. They do not know which way is up and business as usual seems like an old campfire story. Everyone, everywhere is looking for creative ideas to improve their business, and creative ideas is at the heart of true entrepreneurship and innovation.

Within this disruption also lies a few other key support pillars that should benefit all innovative minded individuals.

  • Despite terrible economic conditions, those invested in tech over the past year have done incredibly well. These individuals should be primed to reinvest their profits into bigger wins.
  • The workforce is truly global, and people are scrambling. The ideas of location being an advantage to hiring is truly disappearing. This means talent acquisition costs are falling through the floor and availability through the ceiling.
  • Consumers and businesses alike have been introduced to new technology so the legwork of explaining things such as defi and blockchain is much easier. It's also easy to find numerous use cases for anything involving proximity, health, privacy, and security.
  • The new administration will be eager to find wins, and invest money in different technologies than the previous. No matter what you think politically about this strategy, the reality is that areas such as healthcare, education, and will offer innovation opportunities. Even regulation itself, which we are likely to see increased, can be a great playground for innovation.

Twenty years ago, the way that business was done is unrecognizable in some industries. Many of the successful business today did not even exist then. Technology has a tendency to change things exponentially so imagine what the next ten years will look like. What are we not seeing today that will be the new business as usual?

The future is ours to create

.------

Cody Caillet is the founder at Gulf Coast Solutions, a Houston-based technology firm with speed-to-value approach in delivering business technology to impact top-line and bottom-line numbers for a business.

These 3 Houston researchers are revolutionizing health science innovation

research roundup

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research news, a couple local scientists are honored by awards while another duo of specialists tackle a new project.

University of Houston professor recognized with award

Mehmet Orman of UH has been selected to receive an award for his research on persister cells. Photo via UH.edu

Mehmet Orman, assistant professor of chemical and biomolecular engineering at the University of Houston Cullen College of Engineering has been honored with a Faculty Early Career Development Award from the National Science Foundation. The award comes with a $500,000 grant to study persister cells — cells that go dormant and then become tolerant to extraordinary levels of antibiotics.

"Nearly all bacterial cultures contain a small population of persister cells," says Orman in a news release. "Persisters are thought to be responsible for recurring chronic infections such as those of the urinary tract and for creating drug-resistant mutants."

Previously, Orman developed the first methods to directly measure the metabolism of persister cells. He also developed cell sorting strategies to segregate persisters from highly heterogeneous bacterial cell populations, and, according to the release, he will be using his methods in the NSF research project.

Houston researchers collaborate on oral cancer innovation

Dr. Simon Young of UTHealth and Jeffrey Hartgerink of Rice University are working on a new use for an innovative gel they developed. Photo via Rice.edu

Two Houston researchers — chemist and bioengineer Jeffrey Hartgerink at Rice University and Dr. Simon Young at the University of Texas Health Science Center at Houston — have again teamed up to advance their previous development of a sophisticated hydrogel called STINGel. This time, they are using it to destroy oral cancer tumors.

SynerGel combines a pair of antitumor agents into a gel that can be injected directly into tumors. Once there, the gel controls the release of its cargo to not only trigger cells' immune response but also to remove other suppressive immune cells from the tumor's microenvironment. The duo reported on the technology in the American Chemical Society journal ACS Biomaterials Science & Engineering.

SynerGel, combines a pair of antitumor agents into a gel that can be injected directly into tumors, where they not only control the release of the drugs but also remove suppressive immune cells from the tumor's microenvironment.

"We are really excited about this new material," Hartgerink says in a news release. "SynerGel is formulated from a specially synthesized peptide which itself acts as an enzyme inhibitor, but it also assembles into a nanofibrous gel that can entrap and release other drugs in a controlled fashion.

In 2018, the pair published research on the use of a multidomain peptide gel — the original STINGel — to deliver ADU-S100, an immunotherapy drug from a class of "stimulator of interferon gene (STING) agonists."

The research is supported by the Oral and Maxillofacial Surgery Foundation, the National Institutes of Health, the Welch Foundation, the National Science Foundation and the Mexican National Council for Science and Technology.

Texas Heart Institute researcher honored by national organization

Dr. James Martin of Texas Heart Institute has been named a senior member of the National Academy of Inventors. Photo courtesy of THI

The National Academy of Inventors have named Houston-based Texas Heart Institute's Dr. James Martin, director of the Cardiomyocyte Renewal Lab, a senior member.

Martin is an internationally recognized developmental and regenerative biologist and his research is focused on understanding how signaling pathways are related to development and tissue regeneration.

"Dr. Martin has long been a steward of scientific advancement and has proven to be a tremendous asset to the Texas Heart Institute and to its Cardiomyocyte Renewal Lab through his efforts to translate fundamental biological discoveries in cardiac development and disease into novel treatment strategies for cardiac regeneration," says Dr. Darren Woodside, vice president for research at THI, in a news release. "Everyone at the Texas Heart Institute is thrilled for Dr. Martin, whose induction into the NAI as a Senior Member is well-deserved."

Martin has authored over 170 peer-reviewed papers in top journals he holds nine U.S. patents and applications, including one provisional application, all of which have been licensed to Yap Therapeutics, a company he co-founded.

The full list of incoming NAI Senior Members, which includes three professionals from the University of Houston, is available on the NAI website.

View All Listings